CT
ITCI

Cambridge Trust’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Cambridge Trust’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-500
Closed -$26K – 1205
2021
Q4 		$26K Buy
+500
New +$21K ﹤0.01% 648

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Cambridge Trust's ITCI Position: Q1 2022 in Review

Cambridge Trust sold out of Intra-Cellular Therapies Inc. (ITCI) in Q1 2022, closing a stake of 500 shares — an estimated $26K sold.

Cambridge Trust first reported a position in ITCI in Q4 2021 and held it in 1 quarter. The position peaked at $26K in Q4 2021. 241 funds tracked by Wall St. Rank hold ITCI as of Q1 2022.

  • Cambridge Trust reported no remaining Intra-Cellular Therapies Inc. position as of Q1 2022 after selling out during the quarter.
  • Cambridge Trust sold 500 Intra-Cellular Therapies Inc. shares in Q1 2022, an estimated $26K.
  • Cambridge Trust first reported a position in Intra-Cellular Therapies Inc. in Q4 2021 and held it in 1 quarter.
  • Cambridge Trust's Intra-Cellular Therapies Inc. position peaked at $26K in Q4 2021.
  • 241 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q1 2022.

Based on Cambridge Trust's 13F filing for Q1 2022, filed 12 May 2022.